Frequency, Impact and Health Care Costs of Infantile Hemangioma. Results of A Retrospective German Database Analysis

VA L U E I N H E A LT H 1 9 ( 2 0 1 6 ) A 3 4 7 – A 7 6 6

reduce the period of regeneration after operation, improves the blood circulation in the restorative tissue, and also supports the formation of the structure of the alveolar bone. PSS8 Burden of Disease and Healthcare Costs of Patients Treated with Antiglaucoma Drugs Dondi L1, Calabria S1, De Rosa M2, Maggioni AP3 srl - Collaborative Outcome Research, Bologna, Italy, 2CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, 3ANMCO Research Center, Florence, Italy

1CORE

Objectives: The aim of this study is the analysis of the healthcare pathways of patients treated with antiglaucoma drugs, assessing the healthcare and the economic burden of glaucoma through comorbidities, specific drug prescriptions, hospitalizations and specialist procedures patterns for 2013 and 2014.  Methods: From the ARCO database (about 17 million Italian citizens), a record linkage of free filled drug prescriptions, hospitalizations and specialist procedures data was performed and a cohort of patients treated with antiglaucoma drugs was selected (accrual period: 1 January – 31 December 2013) and followed-up over 12 months from the index date.  Results: From a population of 8,745,228 citizens, a cohort of 177,800 patients with Glaucoma (2.0%) was selected: mean age 71±13 years; 56% females. 22% of them have also Diabetes, 65.9% Hypertension, 9.6% Asthma/COPD and 23.4% are treated with betablockers. Antiglaucoma treatment increases with age for every comorbidity group. Antibacterials for systemic use (54.8%) and agents acting on renin-angiotensin system (53.6%) are the most prescribed during follow-up. Between antiglaucomas, timolol, combinations and plain, is the most prescribed (respectively 33.5% and 26%) with on average 12.4 and 9.9 packs per year, followed by Latanoprost (13.6%). Other specific drugs are prescribed to less than 3% of patients. Among fixed combinations, timolol and bimatoprost is the most prescribed. In all comorbidity groups no differences were found in antiglaucomas prescriptions. The average annual per capita cost of a patient with Glaucoma was 2,552€ , particularly 816€  for drugs, 868€  for hospitalizations and 435€  for outpatient specialist/diagnostic procedures. Patients with Asthma/COPD are the most expensive (3,833€ ).  Conclusions: According to literature, Glaucoma is still highly underdiagnosed, increasing the burden on the NHS for the 50% of patients diagnosed too late. This study can help the health governance to improve clinical and economic decisions for a better disease management based on a patient centered view. PSS9 Frequency, Impact and Health Care Costs of Infantile Hemangioma. Results of A Retrospective German Database Analysis Seiffert A1, Schneider M2, Roessler J3, Larisch K4, Pfeiffer D5 1Gesundheitsforen Leipzig GmbH, Leipzig, Germany, 2Praxis für Kinder- und Jugendmedizin, Bad Rappenau, Germany, 3Universitätsklinikum Freiburg, Freiburg, Germany, 4IGES Institut GmbH, Berlin, Germany, 5Pierre Fabre Dermatologie, Freiburg, Germany

Objectives: To determine the incidence, treatment rate and health care costs of infantile hemangiomas (IH) in Germany by evaluating a sample of patient data of German statutory health insurances.  Methods: A retrospective database analysis from 2007 to 2012 claims data was conducted. Matching of the database used with the overall population covered by German statutory health insurance was confirmed. To describe treatment regimen and costs of infantile hemangioma and identify potential changes over time a search algorithm was developed, thus dividing the study population into three groups: IH patients, IH patients requiring a treatment and IH patients receiving treatment.  Results: Incidence rate detected was 2.0 to 3.2 % for the years analyzed, with a slight increasing trend in most recent years. Detected incidence was lower than previously reported by literature or prospective epidemiologic studies (4-10%). The female: male gender ratio of 1.4: 1 differed from the ratio of 3: 1 reported in literature. Detected treatment rate of IH was 11%. Health care costs during first year of life for infants diagnosed with IH in 2012 were slightly lower (€  2,650) than in average infants (€  2,396), whereas costs for infants treated for IH were considerably higher (€  10,551). The majority of those costs were caused by hospital costs (€ 8,658).  Conclusions: This real-world study was the first to analyze the incidence rate of IH based on claims data from Germany. The detected lower incidence rate may be explained by overestimation of IH in literature, and under-reporting in claims data due to coding issues in a retrospective setting. The detected treatment rate of IH was consistent with literature. Limitations of this study are coding bias, small sample size and claims perspective (non-clinical approach). PSS10 Prevalence and Environmental Risk Factors of Self-Reported Acne in Mexico Poletti-Vasquez DE1, Gomez-Flores M2, Rodriguez M3, Delarue A4, Zkik A5, Chalem Y6, Wolkenstein P7 1DDerma Norte del Bajio, S.C., Aguascalientes,, Mexico, 2Autonome de Nuevo León University, Monterrey, Nuevo León, Mexico, 3Pierre Fabre México, Mexico, Mexico, 4Pierre Fabre DermatoCosmétique, Lavaur, France, 5Pierre Fabre, Boulogne Billancourt, France, 6Pierre Fabre, Boulogne-Billancourt, France, 7Hopital HENRI-MONDOR, Créteil, France

Objectives: Acne vulgaris is one of the most common skin conditions, affecting primarily the adolescents. This disorder is characterized by an abnormal functioning of the pilosebaceous follicle causing different types of lesions. This study aimed at determining the prevalence of self-reported acne in the general Mexican population and to evaluate the impact of environmental and lifestyle factors on this condition.  Methods: A cross-sectional survey using a specifically developed questionnaire, was conducted on a sample of individuals residing in Mexico aged 15 to 65 years, during face to face interviews conducted at their homes. The 15-24 age group, in which prevalence of acne was expected to be the highest, was oversampled. Representativeness was ensured using a quota method considering the geographical region, city districts, age, gender and socio-economic criteria. To account for oversampling, data was weighted for the analyses based on the Mexican population

A563

age distribution.  Results: A total of 4739 questionnaires were analysed yielding an overall prevalence of acne of 10.6% [9.7%-11.5%] in the Mexican population. The prevalence of acne decreased with age, ranging from 21.4% [19.1%-23.6%] in age group 15-24 to 9.9% [8.4%-11.3%] and 3.6% [2.7%-4.4%] in age groups 25-39 and 40-65, respectively. Severity of acne was reported as mild or moderate by over 90% of participants with acne and was consistent across all age groups. Results from a multivariate regression on the subgroup of participants aged 15-24 years, demonstrated that dietary habits such as consumption of dairy products and fried food were risk factors for developing acne whereas occasional alcohol consumption and duration since smoking cessation above 1 year appeared to be protective.  Conclusions: Self-reported acne in Mexico is a frequent skin disease although less prevalent than reported in a European survey. Dietary habits were identified as risk factors for developing acne in the 15-24 age group. PSS11 Incidence of Febuxostat and Allopurinol-Induced Cutaneous Adverse Reaction: A Hospital Based Cohort Study Chang CJ1, Chen C2, Lin YJ2, Chung W2 1Chang Gung University, Tao-Yun, Taiwan, 2Chang Gung Memorial Hospital, Taoyuan City, Taiwan

Objectives: Allopurinol, a xanthine oxidase inhibitor administered orally, primarily to block uric acid production and its complications but with lots of cutaneous adverse drug reactions (cADRs). According to the published statistical report article from Taiwan Drug Relief Foundation in 2013, Allopurinol is ranked the first in application and approval for drug relief cases. Febuxostat is also a drug that inhibits xanthine oxidase, but with fewer cADRs. It was launched in Taiwan in 2013, but research on Taiwan’s experience and patient response is lacking. This study is to explore incidence of cADRs on patients who using Febuxostat and Allopurinol since 2009 using a database from a single hospital in Taiwan.  Methods: Data were captured from database between 2009 and 2014. Patients were defined as the first time using Allopurinol or Febuxostat between 2009 and 2014 and had been used for at least 60 days annually. Descriptive statistics of the incidence for each medication group by year was derived. Fisher’s exact test was used to compare the incidence of cADRs between Allopurinol and Febuxostat annually.  Results: There were 26,502 patients’ information extracted in this study, 22,840 patients were prescribed Allopurinol and 3,662 patients were prescribed Febuxostat. The cumulative incidence rates for ADR were 0.21% and 0% for Allopurinol and Febuxostat respectively between 2009 and 2014. The comparison was statistically significant different in between (p <  0.001). Due to more and more common use of genetic testing (HLA-B*5801) to prevent cADRs for those patients who were prescribed with Allopurinol in Taiwan in recent 3 years, the cADRs incidence was thus became not significant different after 2013 (p= 0.365).  Conclusions: The incidence of cADRs was statistically significant different between Allopurinol and Febuxostat prescribed for patients before the gene test approved and launched in 2013; the difference then become less statistical significant after then. PSS12 Predicting Response To Anti-Vascular Endothelial Growth Factor Treatment Using Electronic Medical Record Data In Eyes With Neovascular Age-Related Macular Degeneration Andrews C1, D’Souza K1, Lacey S1, Rigg J2, Pitcher A2, Milnes F1 Pharma AG, Basel, Switzerland, 2IMS Health, London, UK

1Novartis

Objectives: The objective of this study was to predict ‘non-good’ response for eyes with neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (aVEGF) using ophthalmology electronic medical records (EMR).  Methods: This was a retrospective cohort study with data from ~40 US ophthalmology clinics. ‘Non-good’ response was defined as a best corrected visual acuity (BCVA) gain ≤ 5 letters. Separate models were estimated for the initiation phase (from aVEGF initiation to the visit after the third injection) and the maintenance phase (from the visit after the third injection to twelve months after aVEGF initiation). Predictors captured clinical and demographic attributes. The most recent ~20% of eyes were held back for testing, with the preceding eyes used for training. Random Forests and Logistic Regressions were estimated on the training set and predictions computed for eyes in the test set. The key performance metric was the Area Under the Curve (AUC) based on the test set. Predictor importance was measured as the reduction in AUC associated with randomly permuting values.  Results: The data contained 7,041 eyes for the initiation phase and 6,446 eyes for the maintenance phase. Random Forests outperformed Logistic Regressions. The AUCs for the Random Forests were 0.72 (95%CI 0.69-0.76) and 0.78 (95%CI 0.74-0.81) for the initiation and maintenance phases, respectively. For the Logistic Regressions, the AUCs were 0.70 (95% CI 0.67-0.73] and 0.75 (95%CI 0.71-0.78). The most important predictors for the initiation phase were baseline BCVA and age. For the maintenance phase, the most important predictors were related to BCVA at the start of or prior to the maintenance phase.  Conclusions: This study demonstrated that ophthalmology EMR data can provide accurate predictions of clinical outcomes for eyes with nAMD. This underscores the feasibility of predictive tools to support case management, treatment decisions or physician-patient engagement at the point-of-care. PSS13 Cone Beam Computed Tomography use in Overdenture Abutments Examination: Risk Benefit Analysis Bratus-Hrynkiv R, Kordiyak A Danylo Halytskyi Lviv National Medical University, Lviv, Ukraine

Objectives: Since overdenture treatment as accepted alternative to complete denture fabrication was reintroduced by P.A. Miller (1958) and R.M. Morrow et al. (1969), the problem of the abutment tooth loss is still experienced by overdenture population. Hence, this study aims to investigate the potential of computed radiography in attaining satisfactory overdentures-related clinical outcomes.  Methods: A casecontrol study was conducted among 56 persons-39(69,6%) females and 17(30,4%) males, aged 50-73 years, with terminal mandibular dentition, who received lower